| CEO: | Adrian Kinkaid |
| Chairman: | Simon Gordon Douglas |
| Chief Scientific Officer: | Richard John Buick |
| Non-Executive Dir: | Matthew Baker, Colin Walsh |
| Address: | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Website: | https://www.fusionantibodies.com/ |
| Sector: | Health Care(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BDQZGK16 |
| Currency | UK Pounds |
| Share Price | 13.75p |
| Change Today | -0.50p |
| % Change | -3.51 % |
| 52 Week High | 19.25p |
| 52 Week Low | 5.80p |
| Volume | 264,511 |
| Shares Issued | 113.66m |
| Market Cap | £15.63m |
| RiskGrade | 464 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:20 | 1,701 @ 14.40p |
| 15:48 | 751 @ 14.50p |
| 15:15 | 8,642 @ 14.39p |
| 15:04 | 551 @ 14.40p |
| 14:49 | 5,489 @ 14.40p |
| Chair | Simon Gordon Douglas |
| CEO | Adrian Kinkaid |
You are here: research